Treatment strategies and overall survival for incurable metastatic colorectal cancer – A EURECCA international comparison including 21, 196 patients from the Netherlands and Norway. Issue 6 (June 2020)

• Record Type: Journal Article
• Authors: Breugom, A.J.; Bastiaannet, E.; Guren, M.G.; Kørner, H.; Boelens, P.G.; Dekker, F.W.; Kapiteijn, E.; Gelderblom, H.; Larsen, I.K.; Liefers, G.J.; van de Velde, C.J.H.
• Is Part Of: European journal of surgical oncology. Volume 46:Issue 6(2020)
• Page Start: 1167
• Page End: 1173
• Publication Date: 2020-06
• Subjects: Colorectal cancer -- Metastatic -- Treatment -- National cohort; Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2020.02.005
• Languages: English
• ISSNs: 0748-7983

Abstract

Abstract: Background: The potential benefit of surgery of the primary tumour in patients with asymptomatic metastatic colorectal cancer is debated. This EURECCA international comparison analyses treatment strategies and overall survival in the Netherlands and Norway in patients with incurable metastatic colorectal cancer. Methods: National cohorts (2007–2013) from the Netherlands and Norway including all patients with synchronous metastatic colorectal cancer were compared on treatment strategy and overall survival. Using country as an instrumental variable, we assessed the effect of different treatment strategies on mortality in the first year. Results: Of 21, 196 patients (16, 144 Dutch and 5052 Norwegian), 38.6% Dutch and 51.5% (p < 0.001) Norwegian patients underwent resection of the primary tumour. In the Netherlands, 58.2% received chemotherapy compared with 21.4% in Norway. Radiotherapy was given in 9.5% of Dutch patients and 7.2% of Norwegian patients. Using the Netherlands as reference, the adjusted HR for overall survival was 0.96 (95% CI 0.93–0.99; p = 0.024). Instrumental variable analysis showed an adjusted OR of 1.00 (95% CI 0.99–1.02; p = 0.741). Conclusions: Treatment strategies varied significantly between the Netherlands and Norway, with more surgery and less radiotherapy in Norway. Adjusted overall survival was better in Norway for all patients and patients <75 years, but not for patients ≥75 years. Instrumental variable analysis showed no benefit in one-year mortality for a treatment strategy with a higher proportion of surgery and a lower proportion of radiotherapy. Our findings emphasise the need for further research to select patients with incurable metastatic colorectal cancer for different treatment options.